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ABSTRACT
MicroRNAs (miRNA) have been utilised as a repressor molecule for metastasis of tumours, as it inhibits fundamental processes
related to cellular and physiological pathway of the tumour at the mRNA level. However, therapeutic application of miRNAs
is impaired by premature degradation in the extracellular environment by endonucleases. This research describes the
optimisation, chemical, and morphological characterisation of nanoparticles for effective encapsulation of miRNA-186 and
evaluate its efficiency as anti-metastatic agent in non-small cell lung carcinoma monolayer. Through ionic gelation methods,
the miRNA was encapsulated in chitosan nanoparticles (CNPs), a drug carrier with high particle stability, low cellular toxicity,
and robust preparation methods. Physiochemical and morphological characterization analysis through light scattering analysis
showed miRNA-CNP sizes below 200 nm, with a low polydispersity index and exhibition of irregular spherical shape of the
nanoparticles synthesised through FESEM analysis. Additionally, in vitro nanoparticle efficacy evaluated through scratch
assay suggests a decrease in invasion ability of cancer cells exhibited by miRNA-CNP.
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INTRODUCTION
The global increase in cases and mortality due to
cancer has been significantly alarming, with a
projected 21.7 million new cancer cases and 13
million cancer-afflicted deaths by 2030 (American
Cancer Society, 2015). Locally the age-standardised
incidence rates (ASR) for cancer in 2007 was 179.5
per 100 000 populations, and exponentially
increased 37.74% to 288.3 in 2012 (Ariffin & Nor
Saleha, 2011). Cancer is the uncontrollable growth
of abnormal cells and is often deadly in its malignant
form from which the tumour spreads from the origin
site to other part of body tissues. Termed metastasis,
cancer relapse is highly probable even upon
successful treatment (National Cancer Institute,
2015). Various treatments are presently available to
treat, remove or suppress cancer growth and
metastasis, including surgery, chemotherapy,
radiation, photodynamic, stem cell transplant,
immunotherapy, hormonal therapy, lasers,
complimentary and targeted therapies depending
on a patients’ needs. However, each one of it often
comes with multiple side effects and even worse,
damaging adjacent healthy tissues.
Appropriately, microRNAs (miRNAs) have been
recently established as potential tumour suppressors.
This class of nucleic acid encompass a large family
of non-coding small RNAs which occur as single-
stranded RNAs of approximately 22 nucleotides (nt)
in length (range between 19 to 25 nt) (Ruvkun,
2003). MicroRNAs regulate gene expression by the
sequence-selective targeting of mRNAs, leading to
translational repression or mRNA degradation and
so, they have been implicated in the control of
many fundamental cellular and physiological
processes such as cellular differentiation,
proliferation, apoptosis and stem cell maintenance
(Rothscchild, 2014). Among others, miRNA-186 is
an example of miRNA derived from Homo sapiens
that has been suggested to serve as a tumour-
suppressor in the development and progression of
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non-small cell lung carcinoma (NSCLC). Studies
in 2014 found the expression of miRNA-186 in
NSCLC cells is abrogated and markedly reduced,
resulting in uncontrolled cell cycle progression and
consequently increased cell proliferation (Cai et
al., 2012). Previously, Li et al (2013) identified
pituitary tumour transforming gene (PTTG1)
modulated by miRNA-186 inhibits the invasion and
metastasis of NSCLC through several functional
assays.
Applications of miRNAs in cancer therapy is an
alternative from traditional cancer treatment.
However, as a double stranded nucleic acid, miRNA
is exposed to nuclease degradation (Alexis et al.,
2008), activate innate immune response (Hornung
et al., 2005), and may encounter off-target effects
since miRNA is also capable of affecting multi-
target genes (Conde et al., 2015). On the other hand,
encapsulating therapeutic agents such as miRNA in
polymer nanomaterials such as chitosan nano-
particles confers two main advantages. The first is
miniaturization to sizes below 1000 nm, enabling
the nanoparticles to extravagate through the
endothelium in inflammatory sites, epithelium,
tumours, or microcapillaries (Desai et al., 1997) and
the second is its biodegradability properties allows
a sustain drug release in days or weeks within the
target site (Singh & Lillard, 2009).
Hence, in this study chitosan nanoparticles
(CNP) were used to encapsulate the miRNA-186
through ionotropic gelation methods due to the
materials’ stability, low toxicity, robust preparation
methods, and its ability in controlling the release
of active agents (Nagpal et al., 2010). This study
was aimed at optimising the synthesis of chitosan
nanoparticles to encapsulate miRNA-186, per-
forming morphological characterization and finally
evaluating its efficiency as an anti-metastatic agent
in lung cancer tissue.
MATERIALS AND METHODS
Preparation and synthesis of miRNA-186, CNP
and miRNA-CNP
Bacterial heat shock treatment was used to
transform the precursor miRNA-186 plasmid into
DH5á competent cells. On the following day, single
colonies were grown in Luria broth supplemented
with ampicillin overnight, extracted and analysed
for plasmid concentration at 260nm. The precursor
plasmid was then stored in 4oC until further use.
Chitosan nanoparticles (CNP) were synthesised
using sodium tripolyphosphate (TPP) as a cross-
linker with chitosan (CS) through ionotropic
gelation using modified methods explained
previously (Calvo et al., 1997). Sterilised distilled
water was used to solubilise TPP (1.0 mg/mL in
deionised water) and CS (1.0 mg/mL in acetic acid).
Approximately 0.5 mg/mL of CS and 0.7 mg/mL of
TPP were prepared and subsequently CNP were
prepared at a range of different TPP volumes. For
encapsulation of miRNA-186, the precursor
plasmid was initially complex with CS, followed
by addition of TPP to form miRNA-CNP. The
optimised parameters were then selected to undergo
further analysis.
Characterisation analysis and cellular treatment
Dynamic light scattering (DLS) was used to
determine average size and polydispersity index
(pdi) of CNP with all measurements were made in
triplicate. Field emission scanning electron micro-
scopy (FESEM) was then used for morphological
analysis. Using techniques described by Moutasim
et al (2011) scratch assay technique which provide
straightforward method, have particular suitability
to study cell migration by cell-cell interaction in
vitro and mimics almost similar behaviour on the
migration of cells in vivo (Liang et al., 2007) was
used to access the invasiveness of A549 non-small
cell lung carcinoma at different time points by
creating a “wound” in monolayer of A549 cells then
their ability to migrate and closing the wound was
measured and assessed using inverted microscope
(Moutasim et al., 2011).
Technically, A549 cell were seeded and
achieved 80-90% confluency in 24-well plate prior
to treatment. On the treatment day, media was
removed, monolayer cell scratched using 200 μl tip
and rinsed with 1% of phosphate buffered saline
(PBS). miRNA-CNP, CNP and miRNA-186 alone was
added to the cell respectively and as control,
complete growth media was added in another well.
Cells were viewed under microscope at several time
points. The distance of the scratch created was
measured and three replicate of treatments were
made.
Statistics
Each group of data are expressed as mean ± SEM
and two-way ANOVA with Bonferroni Test was
performed using GraphPad Prism version 5.02 (for
Windows, GraphPad Software, San Diego California
USA). Statistically significant was considered when
p < 0.05, p < 0.01 or p < 0.001.
RESULTS AND DISCUSSION
Morphological characterization of nanoparticles
synthesised
CNP and miRNA-CNP samples were
successfully synthesised through ionic gelation
methods. The average size of samples should be
below 1000 nm which indicate nanoparticles size
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while low polydispersity index (pdi) representing
single size mode and low aggregations. Figure 1A
and 1B represents the particle size and pdi of
samples following synthesis. The precursor miRNA-
186 used prior encapsulation conferred high pdi
values, with sizes less than 12 nm and show
various irregular shapes of the plasmid through
morphological analysis (Figure 2B). A range of TPP
volumes were then used to synthesise CNP, with
optimised parameter determined at 200 ul TPP as
presented in Figure 1A; with a particle size around
100 nm. This parameter also exhibited the lowest
pdi value, indicating a low aggregation of
synthesised CNP. This parameter was further used
to optimise encapsulation of miRNA-186 in CNP.
Intuitively, different volumes of miRNA-186
were used for encapsulation and results were
optimised using 100 ml. Trends showed an increase
in particle size (Figure 1A) thus suggesting the
formation of nanoparticles with the precursor
plasmid within the CNP core. Particle size for
miRNA-186 encapsulated-CNP correlated with pdi
values below 0.5 in Figure 1B and increased
particle morphology (Figure 2D), compared to CNP
samples (Figure 2C). The spherical shape of both
synthesised nanoparticles possess a higher surface
area as compared to other possible shapes (Ismail
et al., 2015). Explicitly, particle size of optimized
CNP was 111.80 nm and increased 97.25% to
220.53 nm upon addition of 100ul miRNA-186;
this parameter further utilised in cellular treatments
of A549 lung cancer cells. Therefore, it was assumed
that miRNA-186 was successfully encapsulated in
CNP at 90ng/ml. Theoretically, the formation of
both CNP and miRNA-186 encapsulated-CNP
occurred through an electrostatic interaction of
oppositely charged polymers (Kauper & Forrest,
2012). Protonated amine groups of CS electro-
statically bind to anionic phosphate group of TPP
and/or miRNA which finally produced smaller and
fine nanoparticles (Katas & Alpar, 2006).
Nanoparticle efficacy through cellular treatment
Scratch assay was performed by making scratch
wounds on a cell monolayer grown on 24-well
plates. The ability of cancer cells to close the wound
gap was observed at several time points to stimulate
metastasis processes in vitro. In Figure 3, A549
cancer cells without any treatments (control) was
shown to grow and close the scratched gap rapidly
within a 48 hour timeframe with 60% decrease in
length. Interestingly, both miRNA-CNP and CNP
alone significantly hindered the migration rate of
A549 cells when compared with control group
through 48 hours observation. Specifically, A549
cells treated with miRNA-186 encapsulated-CNP
shown an increase in gap distance at 19% with
clusters of cells floating and clumping in media.
Meanwhile, treatment using CNP caused a slightly
increase of the gap at only 1.1% within 48 hours
with CNP exhibits potential inhibition to invasion
properties of the cancer cells. Loch-Neckel et al
(2015) observed a similar effect of chitosan-coated
nanoparticles containing curcumin (Cur-CCNP) on
melanoma cells assessed using the scratch assay.
Treatment of Cur-CCNP had prevented cellular
growth in the scratched area while free curcumin
hampered cell migration and also induced cellular
death (Loch-Neckel et al., 2015). In contrast, directly
treated miRNA-186 caused floating and clumping
of cells without visible scratched gap since the first
hour. Similarly, transducing naked miRNA-186 has
been reported to slow down A549 cells as analysed
using MTT assay (Cai et al., 2012). Due to this
observation, it is worth noting that the mechanisms
and elucidation of intake, release and action of this
system would govern more insight in future studies.
Fig. 1. Light scattering data of (A) particle size & (B) polydispersity index of optimized CNP, miRNA-CNP and miRNA-
186. Data were obtained in triplicate and presented as mean ± SEM.
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Fig. 2. FESEM analysis on morphology of (A) chitosan, (B) miRNA-186, (C) CNP and (D) miRNA-186
encapsulated-CNP at 100,000x magnification.
CONCLUSION
Through this study, miRNA-186 was successfully
encapsulated in CNP based on results obtained
through DLS analysis and FESEM images. When
introduced to A549 lung cancer cells, miRNA-186
encapsulated in CNP showed an ability to reduce
cell invasion, possibly caused by inhibition of cell
proliferation. Therefore, miRNA-186 encapsulated-
CNP is suggested to possess an anti-metastatic
in A549 lung cancer cells, and governs further
exploration of the miRNA-186 delivery system into
cancer cells.
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